KYORIN Holdings, Inc. Announces Consolidated Earnings Results for the Six Months Ended September 30, 2017; Provides Earnings Guidance for the Fiscal Year Ending March 31, 2018; Announces Dividend for the Second Quarter Ended September 30, 2017, Payable on December 4,2017; Provides Dividend Forecast for the Fiscal Year Ending March 31, 2018
November 06, 2017
Share
KYORIN Holdings, Inc. announced consolidated earnings results for the six months ended September 30, 2017. For the period, the company reported Net Sales were ¥50,758 million against ¥54,628 million a year ago. Operating income was ¥1,443 million against ¥3,663 million a year ago. Ordinary income was ¥1,693 million against ¥3,921 million a year ago. Profit attributable to owners of parent was ¥1,240 million against ¥2,684 million a year ago. Net income per share was ¥16.86 against ¥36.56 a year ago.
The company provides earnings guidance for the fiscal year ending March 31, 2018. The company forecast Net Sales were ¥50,758 million against ¥54,628 million a year ago. Operating income was ¥1,443 million against ¥3,663 million a year ago. Ordinary income was ¥1,693 million against ¥3,921 million a year ago. Profit attributable to owners of parent was ¥1,240 million against ¥2,684 million a year ago. Net income per share was ¥16.86 against ¥36.56 a year ago. Return on equity ratio of 82.9% against 81.9% a year ago.
The company announced dividend for the second quarter ended September 30, 2017. For the second quarter, the company announced dividend of ¥20 against ¥20 in the same period a year ago. The scheduled date for starting dividend payment is December 4, 2017.
The company provides dividend forecast for the fiscal year ending March 31, 2018. For the fiscal year, the company expects to pay dividend of ¥58 per share.
Kyorin Pharmaceutical Co Ltd, formerly Kyorin Holdings Inc, is a Japan-based company mainly engaged in the pharmaceuticals business. The Pharmaceuticals segment is mainly engaged in the manufacture, purchase, sales and testing of pharmaceutical products, the purchase of raw materials for pharmaceuticals, the evaluation of technologies, the inspection, analysis and negotiation of license affiliations, the operations related to clinical trials and information gathering such as searching for drug discovery seeds, as well as the drug candidate compound discovery research and compound evaluation business. The Company also conducts the diagnostic businesses and verifies and creates research targets that are directly linked to drug discovery.
KYORIN Holdings, Inc. Announces Consolidated Earnings Results for the Six Months Ended September 30, 2017; Provides Earnings Guidance for the Fiscal Year Ending March 31, 2018; Announces Dividend for the Second Quarter Ended September 30, 2017, Payable on December 4,2017; Provides Dividend Forecast for the Fiscal Year Ending March 31, 2018
KYORIN PHARMACEUTICAL CO., LTD. 
